| Date | Title | Description |
| 02.09.2026 | С первого дубля | С первого дубля Иностранные инновации в фармацевтике появятся в стране через российские копии
С марта 2026 года Минздрав одобрил клинические исследования (КИ) как минимум семи инновационных разработок иностранных компаний, которые только не... |
| 02.07.2026 | Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH | SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pha... |
| 21.03.2026 | Condor Software Secures $24M to Revolutionize Life Sciences Financial Intelligence | Condor Software, a San Diego innovator, secured $24 million in Series A funding. This pivotal round, led by Insight Partners, propels the company's total capital to $36 million. Condor fundamentally transforms life sciences financial operat... |
| 19.03.2026 | Condor Software: $24 Million Raised To Build Financial Intelligence Platform For Life Sciences | Condor Software announced it has raised $24 million in a Series A funding round led by Insight Partners, with participation from Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures, and Bramalea Partners. The company has no... |
| 27.02.2026 | Global Pharma Giants Bet Big on China's Weight-Loss Innovations | Pfizer significantly invests in China's surging weight-loss drug market. A landmark partnership with Sciwind Biosciences grants Pfizer exclusive commercialization rights for Ecnoglutide, a cutting-edge GLP-1 receptor agonist, in mainland Ch... |
| 25.02.2026 | Pfizer, Other Global Pharma Giants Are Pouring Big Bucks Into Licensing Chinese Weight-Loss Drugs | (Yicai) Feb. 25 -- Global pharmaceutical heavyweights, including the likes of Pfizer and AstraZeneca, are shelling out huge sums to secure the licensing rights to Chinese weight-loss drugs, as a fierce scramble for next-generation obesity t... |
| 11.02.2026 | Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH | SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entere... |
| 14.10.2025 | HepQuant Announces Exciting New Data Utilizing HepQuant DuO® testing: Early Assessment of Resmetirom Treatment Benefit in Patients with Compensated MASH Cirrhosis | HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announces promising findings from a study utilizing the HepQuant DuO test to evaluate the impact of resmetirom treatment in patients wit... |
| 18.08.2025 | Novo Nordisk shares pop after Wegovy receives U.S. approval for liver disease | Novo Nordisk’s Wegovy was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis.
It marks the first GLP-1 class therapy to be cleared for MASH.
... |
| 19.12.2024 | The Shifting Sands of Pharma and Energy: Opportunities Amidst Uncertainty | In the world of finance, change is the only constant. Two sectors currently in the spotlight are pharmaceuticals and energy. Both face unique challenges and opportunities. Investors must navigate these shifting sands carefully.
Novo Nordisk... |
| 18.12.2024 | Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. |
Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: NVO). The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide. Marketed th... |
| 07.05.2024 | Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates | On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis
In April 2024, product shipped and first p... |
| 06.03.2024 | Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | - |
| 05.03.2024 | Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis | - |
| 10.11.2023 | Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health | Data to be featured in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting®
Analyses from comprehensive set of noninvasive tests used in MAESTRO-NASH provide new insights on strategies to i... |
| 28.04.2023 | Current NASH treatment hurdles highlighted, new drugs hailed as game-changers | Michael Betel, President and Founder of the Fatty Liver Alliance testifies at ICER.
Fatty Liver Alliance advocates about the importance of 2 new NASH treatments soon to be approved.
ICER welcomes public comments and discussion about new NAS... |
| 21.12.2022 | Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program | - |
| 19.12.2022 | Madrigal Pharmaceuticals Stock More Than Doubles on ‘NASH’ Breakthrough | After years of failed efforts to find a treatment for the liver condition known as NASH, biotechnology firm Madrigal Pharmaceuticals delivered an unexpected success on Monday.
In a Phase 3 trial of its drug resmetirom, Madrigal (ticker: MDG... |
| 19.12.2022 | A tiny biotech's experimental treatment for a silent disease that strikes millions just cleared a key hurdle and the stock is up more than 200% | Madrigal Pharmaceuticals is hoping to succeed where others have failed in treating NASH, a serious liver disease. Pramote Polyamate/Getty Images
Madrigal Pharmaceuticals reported positive results in its phase 3 trial for a drug to treat NAS... |
| 08.06.2021 | MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences | WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet me... |
| 12.10.2018 | Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis | Full article from Dermira
MENLO PARK, Calif., Sept. 5, 2018 – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the milli... |
| 31.05.2018 | Madrigal Achieves Liver Biopsy Endpoints in Patients with NASH | Full article from Madrigal Pharmaceuticals
CONSHOHOCKEN, Pa., May 31, 2018 — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced positive top-line, 36-week results from a Phase 2 clinical trial in patients with biopsy-proven non-... |
| 04.01.2018 | Madrigal: This Year’s Best Midcap Stock Was Virtually Unknown 6 Months Ago | Article in Bloomberg
Madrigal Pharmaceuticals Inc. — a player in the blockbuster contest to develop treatments for the liver disease known as NASH — surged more than 500 percent this year, poised to finish 2017 as the best performing stock... |
| 06.12.2017 | Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial | Full Press Release from Madrigal
— Statistically significant improvement in the relative decrease in liver fat in patients treated with MGL-3196 compared with placebo, determined by magnetic resonance imaging-estimated proton density fat f... |
| 20.10.2016 | Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in NASH Patients | Conshohocken, PA — Madrigal Pharmaceuticals, Inc. (MDGL) today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of non-alcoholic steatohepatitis (NASH). MGL-3196 is a first-in-class, oral, o... |
| 14.04.2016 | Madrigal and Synta Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company | Fort Washington, PA and Lexington, MA — Synta Pharmaceuticals Corp. (“Synta”) (NASDAQ:SNTA) and Madrigal Pharmaceuticals, Inc., a privately-held company (“Madrigal”), today announced that they have entered into a definitive merger agreement... |
| - | FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease | The Food and Drug Administration approved Rezdiffra as the first-ever treatment for a common and potentially deadly liver disease that affects millions worldwide.
The FDA’s decision means Madrigal Pharmaceuticals has succeeded in a disease ... |
| - | 10 US colleges and universities where female grads have gone on to secure more than $1 million in funding for their startups | Stanford graduate Katrina Lake founded Stitch Fix, an online personal styling service valued at $1.4 billion at its IPO. Stitch Fix
To date, there have been some 6,940 female company founders whose businesses have received more than $1 mill... |
